{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:57:33Z","timestamp":1788872253948,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.urolonc.2019.07.009","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:22:36Z","timestamp":1566865356000},"page":"991-998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study"],"prefix":"10.1016","volume":"37","author":[{"given":"Jiahua","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2019.07.009_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0002","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s11427-017-9172-6","article-title":"Trend analysis of cancer incidence and mortality in China","volume":"60","author":"Wei","year":"2017","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/hyw034","article-title":"Urologic cancer in China","volume":"46","author":"Pang","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2019.07.009_bib0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2009.05.001","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0006","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multi-arm, multistage, platform randomized controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2019.07.009_bib0007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clgc.2015.10.008","article-title":"Neoadjuvant systemic therapy before radical prostatectomy in high-risk prostate cancer does not increase surgical morbidity: contemporary results using the clavien system","volume":"14","author":"Williams","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0008","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2007.06760.x","article-title":"Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer","volume":"100","author":"Prayer-Galetti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1756-8722-7-20","article-title":"Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk PCa","volume":"7","author":"Thalgott","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2019.07.009_bib0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.bjc.6605320","article-title":"Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer","volume":"101","author":"Mellado","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0011","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health. Natl Cancer Inst. Published: November 27, 2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"5","key":"10.1016\/j.urolonc.2019.07.009_bib0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00345-008-0250-7","article-title":"High-risk PCa in the United States, 1990\u20132007","volume":"26","author":"Cooperberg","year":"2008","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0014","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1464-410X.2011.10514.x","article-title":"Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk PCa","volume":"109","author":"Pierorazio","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized PCa: definition and outcomes","volume":"17","author":"Debasish","year":"2014","journal-title":"PCa Prostatic Dis"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11934-016-0592-4","article-title":"Neoadjuvant treatment of high-risk, clinically localized PCa prior to radical prostatectomy","volume":"17","author":"Pietzak","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.urolonc.2014.11.020","article-title":"Chemotherapy and novel therapeutics before RP for high-risk clinically localized PCa","volume":"33","author":"Cha","year":"2015","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2019.07.009_bib0018","first-page":"220","article-title":"Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells","volume":"6","author":"Tso","year":"2000","journal-title":"Cancer J"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0019","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1511800","article-title":"Chemohormonal therapy in hormone-sensitive PCa","volume":"374","author":"Ciccarese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10147-017-1160-8","article-title":"Overall survival of high-risk PCa patients who received neoadjuvant chemohormonal therapy followed by RP at a single institution","volume":"22","author":"Fujita","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12032-017-1050-y","article-title":"Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk PCa patients treated with RP: a multi-institutional analysis","volume":"34","author":"Matsumoto","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0022","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced PCa","volume":"15","author":"Tannock","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2019.07.009_bib0023","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12676","article-title":"Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by RP for patients with clinically localised, high-risk PCa","volume":"116","author":"Silberstein","year":"2015","journal-title":"BJU Int"},{"issue":"suppl 1(62)","key":"10.1016\/j.urolonc.2019.07.009_bib0024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2003.09.052","article-title":"Cancer and leukemia group B (CALGB) 90203: a randomized phase 3 study of RP alone versus estramustine and docetaxel before RP for patients with high-risk localized disease","volume":"29","author":"Eastham","year":"2003","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2019.07.009_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2008.04.012","article-title":"Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer","volume":"180","author":"Chi","year":"2008","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2019.07.009_bib0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bju.12797","article-title":"Laparoscopic RP for high-risk PCa","volume":"115","author":"Benedetto","year":"2015","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.urolonc.2019.07.009_bib0027","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.urolonc.2018.07.020","article-title":"The addition of chemotherapy in the definitive management of high risk prostate cancer","volume":"36","author":"Ferris","year":"2018","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:17:12Z","timestamp":1761041832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919302856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1078143919302856"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.07.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}